Download PDF
Int J Angiol
DOI: 10.1055/s-0044-1791556
Review Article

A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction

Vaishali R. Undale
1   Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India
,
Shweta K. Lembhe
1   Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India
,
Shital D. Satone
1   Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India
,
Pratiksha Hase
1   Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Myocardial infarction is the permanent death (necrosis) of heart muscle caused by a lack of oxygen for an extended period of time (ischemia). Since the very first percutaneous transluminal coronary angioplasty was done 40 years ago, the science of interventional cardiology has advanced dramatically. The above progression began with a balloon catheter attached to a fixed wire, advancing to bare-metal stents, first-generation drug-eluting stents (DES), second- and third-generation biodegradable polymer-based DES. Ultimately, bioabsorbable stents are still in development. Zotarolimus is a new pharmacologic therapy with a similar reprint address; for example, the antirestenosis agent sirolimus has recently been investigated as part of a stent platform combined with a biomimetic phosphorylcholine and BioLINX polymer for its biological activity, as well as its usefulness as an antiproliferative agent. Several clinical trials have been conducted to assess the safety and efficacy of the zotarolimus drug-eluting stent (Z-DES). Medtronic Medical Devices, a global leader in medical technology (United States), and Abbot Global Health Care and Research began clinical trials on the Z-DES in 2002 and will continue through 2021 (INDIA). Endeavor (E-Zes), Resolute (R-Zes), Resolute Integrity (I-Zes), and Resolute Onyx are the different forms of Z-DES that Medtronic has tested in clinical trials. In comparison to other DES, Z-DES was found to be safe in these clinical trials done across multiple nations and in a diverse demographic. This review helps understand the overall clinical trial of Z-DES.

Keywords

myocardial infarction - coronary artery intervention - coronary lesion - angioplasty - restenosis - thrombosis

Authors' Contributions

S.K.L. led the concept development, literature collection, and manuscript compilation. S.D.S. was responsible for data collection, drafting, and diagram designing. V.R.U. provided mentoring, reviewed the literature, and oversaw the final compilation, offering supervisory guidance throughout. Meanwhile, P.H. handled the final drafting, editing, and manuscript preparation according to author guidelines. All authors collaborated on compiling the manuscript, with S.K.L., S.D.S., and P.H. conceptualizing and drafting the initial version, and V.R.U. providing expert review and editing.




Publication History

Article published online:
21 October 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Yang JX, Yeh RW. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review. Future Cardiol 2018; 14 (03) 251-267
    CrossrefPubMedSearch in Google Scholar
  • 2 Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010; 105 (01) 3A-9A
    CrossrefPubMedSearch in Google Scholar
  • 3 Smilowitz NR, Feit F. The history of primary angioplasty and stenting for acute myocardial infarction. Curr Cardiol Rep 2016; 18 (01) 5
    CrossrefPubMedSearch in Google Scholar
  • 4 Byrne RA, Stone GW, Ormiston J, Kastrati A. Coronary balloon angioplasty, stents, and scaffolds. Lancet 2017; 390 (10096): 781-792
    CrossrefPubMedSearch in Google Scholar
  • 5 Canfield J, Totary-Jain H. 40 Years of percutaneous coronary intervention: history and future directions. J Pers Med 2018; 8 (04) 33
    CrossrefPubMedSearch in Google Scholar
  • 6 Yeh RW, Silber S, Chen L. et al. 5-Year safety and efficacy of resolute zotarolimus-eluting stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv 2017; 10 (03) 247-254
    CrossrefPubMedSearch in Google Scholar
  • 7 Bønaa KH, Mannsverk J, Wiseth R. et al; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016; 375 (13) 1242-1252
    CrossrefPubMedSearch in Google Scholar
  • 8 Räber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011; 29 (03) 176-189
    CrossrefPubMedSearch in Google Scholar
  • 9 Windecker S, Latib A, Kedhi E. et al; ONYX ONE Investigators. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 2020; 382 (13) 1208-1218
    CrossrefPubMedSearch in Google Scholar
  • 10 Im E, Hong MK. Drug-eluting stents to prevent stent thrombosis and restenosis. Expert Rev Cardiovasc Ther 2016; 14 (01) 87-104
    CrossrefPubMedSearch in Google Scholar
  • 11 Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006; 19 (05) 405-413
    CrossrefPubMedSearch in Google Scholar
  • 12 Serruys PW, Silber S, Garg S. et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363 (02) 136-146
    CrossrefPubMedSearch in Google Scholar
  • 13 Palmerini T, Biondi-Zoccai G, Della Riva D. et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting?. J Am Coll Cardiol 2013; 62 (21) 1915-1921
    CrossrefPubMedSearch in Google Scholar
  • 14 Roguin A. Stent: the man and word behind the coronary metal prosthesis. Circ Cardiovasc Interv 2011; 4 (02) 206-209
    CrossrefPubMedSearch in Google Scholar
  • 15 Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ 2003; 326 (7398) 1080-1082
    CrossrefPubMedSearch in Google Scholar
  • 16 Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull 2013; 106 (01) 193-211
    CrossrefPubMedSearch in Google Scholar
  • 17 Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316 (12) 701-706
    CrossrefPubMedSearch in Google Scholar
  • 18 Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100 ( 8B): 36M-44M
    CrossrefPubMedSearch in Google Scholar
  • 19 Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen YX, O'Brien ER. The evolution of coronary stents: a brief review. Can J Cardiol 2014; 30 (01) 35-45
    CrossrefPubMedSearch in Google Scholar
  • 20 Valgimigli M, Patialiakas A, Thury A. et al; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65 (08) 805-815
    CrossrefPubMedSearch in Google Scholar
  • 21 Chen Y-W, Smith ML, Sheets M. et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol 2007; 49 (04) 228-235
    CrossrefPubMedSearch in Google Scholar
  • 22 Bonow RO, Mann DL, Zipes DP. et al. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences;; 2011
    Search in Google Scholar
  • 23 Zotarolimus. ChemDraw—PerkinElmer Informatics. 2021
    PubMedSearch in Google Scholar
  • 24 Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006; 58 (03) 437-446
    CrossrefPubMedSearch in Google Scholar
  • 25 clinicaltrial.gov. August 3, 2021 . Accessed September 10, 2024 at: https://clinicaltrials.gov/
    PubMed
  • 26 Meredith IT, Ormiston J, Whitbourn R. et al; ENDEAVOR I Investigators. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 2007; 100 (8B): 56M-61M
    CrossrefPubMedSearch in Google Scholar
  • 27 Schultheiss HP, Grube E, Kuck KH. et al. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 2007; 3 (01) 76-81
    PubMedSearch in Google Scholar
  • 28 Eisenstein EL, Leon MB, Kandzari DE. et al; ENDEAVOR III Investigators. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009; 2 (12) 1199-1207
    CrossrefPubMedSearch in Google Scholar
  • 29 Kirtane AJ, Leon MB, Ball MW. et al; ENDEAVOR IV Investigators. The “final” 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013; 6 (04) 325-333
    CrossrefPubMedSearch in Google Scholar
  • 30 Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT. E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009; 2 (12) 1227-1235
    CrossrefPubMedSearch in Google Scholar
  • 31 Tavella R, Ranasinghe I, Zeitz C, Beltrame JF. Post-Percutaneous Coronary Intervention Angina: A New Performance Measure?. JACC Cardiovasc Interv 2015; 8 (12) 1639-1640
    CrossrefPubMedSearch in Google Scholar
  • 32 Sen H, Lam MK, Löwik MM. et al. Clinical events and patient-reported chest pain in all-comers treated with Resolute Integrity and Promus Element stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II). JACC Cardiovasc Interv 2015; 8 (07) 889-899
    CrossrefPubMedSearch in Google Scholar
  • 33 Zocca P, Kok MM, Tandjung K. et al. 5-Year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. JACC Cardiovasc Interv 2018; 11 (05) 462-469
    CrossrefPubMedSearch in Google Scholar
  • 34 Blum M, Cao D, Mehran R. Device profile of the Resolute Onyx zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy. Expert Rev Med Devices 2020; 17 (04) 257-265
    CrossrefPubMedSearch in Google Scholar
  • 35 Tam CC, Chan K, Lam S. et al. One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent. J Int Med Res 2018; 46 (01) 457-463
    CrossrefPubMedSearch in Google Scholar
  • 36 Price MJ, Shlofmitz RA, Spriggs DJ. et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. Catheter Cardiovasc Interv 2018; 92 (02) 253-259
    CrossrefPubMedSearch in Google Scholar
  • 37 Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: development and challenges. Int J Clin Pharm 2018; 40 (04) 823-831
    CrossrefPubMedSearch in Google Scholar
  • 38 von Birgelen C, Zocca P, Buiten RA. et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet 2018; 392 (10154): 1235-1245
    CrossrefPubMedSearch in Google Scholar
  • 39 Kedhi E, Latib A, Abizaid A. et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. Am Heart J 2019; 214: 134-141
    CrossrefPubMedSearch in Google Scholar
  • 40 Steinfeld DS, Liu AP, Hsu SH. et al. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression. J Cardiovasc Pharmacol 2012; 60 (02) 179-186
    CrossrefPubMedSearch in Google Scholar
  • 41 Alfonso F, Fernandez C. Second-Generation Drug-Eluting Stents: Moving the Field Forward. Washington, DC:: American College of Cardiology Foundation;; 2011: 26-29
    Search in Google Scholar
  • 42 Wiemer M, Stojkovic S, Samol A. et al. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol 2017; 16 (01) 1-13
    PubMedSearch in Google Scholar
  • 43 Sammel AM, Chen D, Jepson N. New generation coronary stent technology—is the future biodegradable?. Heart Lung Circ 2013; 22 (07) 495-506
    CrossrefPubMedSearch in Google Scholar
  • 44 Bennett J, Dubois C. Percutaneous coronary intervention, a historical perspective looking to the future. J Thorac Dis 2013; 5 (03) 367-370
    PubMedSearch in Google Scholar